Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone sodium phosphate is a synthetic adrenocortical steroid and a water-soluble inorganic ester of dexamethasone, classified as a glucocorticoid. It is used primarily for its potent anti-inflammatory and immunosuppressive effects across multiple organ systems. The drug acts by binding to the glucocorticoid receptor, modulating gene expression to suppress inflammatory responses and immune activity. Dexamethasone sodium phosphate has rapid onset but short duration of action compared to less soluble corticosteroid preparations, making it suitable for acute conditions responsive to steroid therapy. Indications include endocrine disorders (such as adrenal insufficiency), rheumatic disorders (like rheumatoid arthritis), severe allergic reactions, certain skin diseases, eye inflammation, gastrointestinal diseases (e.g., ulcerative colitis), blood disorders, respiratory conditions (e.g., asthma), cerebral edema, neoplastic diseases (such as leukemia or lymphoma symptom relief), shock unresponsive to conventional therapy if adrenal insufficiency exists or is suspected, and other inflammatory or autoimmune conditions[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone sodium phosphate.